10-K: TScan Therapeutics Shifts Focus to Heme, Pauses Solid Tumor Trial

TScan Therapeutics reports increased net losses in 2025, strategically prioritizes its hematologic malignancies program, and pauses solid tumor trial enrollment to focus on in vivo engineering.

Summary

• TScan Therapeutics reported a net loss of $129.8 million for the year ended December 31, 2025, an increase from $127.5 million in 2024.
• The accumulated deficit reached $504.9 million as of December 31, 2025.
• Cash and cash equivalents stood at $152.4 million as of December 31, 2025, with existing capital expected to fund operations into the second half of 2027.
• A strategic decision was made on November 3, 2025, to prioritize the heme malignancies program (TSC-101, TSC-102-A01, TSC-102-A03) and pause further enrollment in the solid tumor Phase 1 trial (PLEXI-T).
• This strategic shift included a workforce reduction of approximately 30%, or 66 roles, expected to generate $45.0 million in annual cost savings in 2026 and 2027.
• The company reached an agreement with the FDA on a registrational path forward for the TSC-101 program for AML and MDS, with a pivotal study mirroring the ongoing Phase 1 ALLOHA study.
• Updated results from the ALLOHA Phase 1 trial (as of September 19, 2025) showed durable responses, with 3 of 3 (100%) patients 2-years post-HCT in the TSC-101 treatment arm showing no evidence of disease, compared to 1 of 4 (25%) in the control arm.
• Relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) favored the treatment arm in the ALLOHA trial.
• TSC-101 infusions were generally well-tolerated at all three dose levels with no dose-limiting toxicities.
• A new commercial-ready manufacturing process for TSC-101 reduces manufacturing time from 17 days to 12 days and has shown promising significant reduction in ex vivo expansion.
• FDA cleared IND applications for TSC-102-A01 and TSC-102-A03, expanding the hematologic malignancies program to target CD45 in patients with HLA types A*01:01 and A*03:01, respectively.
• The solid tumor Phase 1 trial (PLEXI-T) treated seven patients with singleplex therapy (one confirmed partial response, three stable disease, two progressive disease) and two patients with multiplex therapy (both progressive disease).
• Preclinical efforts for solid tumors are now focused on in vivo engineering, leveraging a lentiviral-based platform through a third-party partnership.
• The company is also leveraging its target discovery platform to identify targets for T cell-driven autoimmune disorders, with initial indications including ankylosing spondylitis, ulcerative colitis, and scleroderma.
• Revenue from the collaboration agreement with Amgen Inc. was $10.3 million in 2025, up from $2.8 million in 2024, with potential for over $500 million in success-based milestone payments and tiered single-digit royalties.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While the progress in the heme program and strategic focus are positive, the increased net loss, higher cash burn, and the pause in the solid tumor clinical trial indicate significant ongoing financial and developmental challenges. The need for substantial future funding also weighs on the sentiment.

Positives

• Agreement with the FDA on a registrational path for TSC-101 in AML and MDS, providing a clear development pathway.
• Positive early clinical data for TSC-101 in the ALLOHA Phase 1 trial, demonstrating durable responses with 100% of 3 evaluable patients 2-years post-HCT showing no evidence of disease, significantly better than the 25% in the control arm.
• Relapse-free survival (HR=0.50) and overall survival (HR=0.61) favored the treatment arm in the TSC-101 trial, indicating potential clinical benefit.
• TSC-101 infusions were generally well-tolerated across all dose levels with no dose-limiting toxicities, suggesting a favorable safety profile.
• A new commercial-ready manufacturing process for TSC-101 reduces manufacturing time from 17 days to 12 days and shows promising reduction in ex vivo expansion, enhancing efficiency and scalability.
• FDA clearance of IND applications for TSC-102-A01 and TSC-102-A03 expands the heme program to additional HLA types, broadening the potential patient population.
• Strategic prioritization and workforce reduction are expected to yield significant annual cost savings of $45.0 million in 2026 and 2027.
• The collaboration with Amgen provides a $30.0 million upfront payment and eligibility for over $500 million in success-based milestone payments and tiered single-digit royalties, offering substantial non-dilutive funding potential.
• Expansion of target discovery capabilities to include CD4+ T-cells and MHC Class II antigen presentation opens new avenues for T cell-mediated autoimmune disorder treatments.

Negatives

• Net loss increased to $129.8 million in 2025 from $127.5 million in 2024, indicating continued significant cash burn.
• Accumulated deficit of $504.9 million as of December 31, 2025, highlights substantial historical losses.
• The strategic decision to pause further enrollment in the solid tumor Phase 1 trial (PLEXI-T) and refocus preclinical efforts suggests challenges or suboptimal results in the ex vivo solid tumor program.
• Patients treated with multiplex therapy in the PLEXI-T study did not receive the target dose and both showed evidence of disease progression, indicating efficacy challenges in this cohort.
• The company will need to obtain substantial additional funding to complete the development and commercialization of its product candidates, as existing cash is only sufficient into H2 2027.
• A 30% workforce reduction (66 roles) may lead to loss of institutional knowledge and expertise, and potential impacts on employee morale and productivity.
• Limited operating history and direct experience as a company in conducting clinical trials and managing manufacturing facilities pose inherent risks.
• The market opportunities for product candidates may be relatively small, and estimates of target patient populations could be inaccurate.
• The biotechnology industry is characterized by intense competition, with many larger companies possessing greater resources.
• Reliance on single or sole source suppliers for critical raw materials and reagents creates supply chain vulnerability.

Risks

• We have incurred significant losses since inception, expect to incur losses over the next several years, and may not be able to achieve or sustain revenues or profitability in the future.
• Our business depends upon the success of our proprietary platform, which represents a novel approach to cancer treatment and creates significant challenges.
• Our limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.
• We have never generated any revenue from sales of our TCR-T therapy product candidates, and our ability to generate revenue and become profitable depends significantly on our success in a number of areas.
• We will need to obtain substantial additional funding to complete the development and any commercialization of our product candidates; inability to raise capital could force delays, reductions, or elimination of programs.
• Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our intellectual property or product candidates on unfavorable terms.
• Global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships, and conflicts could make it more difficult to access financing and adversely affect business.
• The U.S. Congress and the Trump administration have made and may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.
• Recent volatility in capital markets and lower market prices for many securities may affect our ability to access new capital, impacting liquidity and growth.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations and financial condition.
• The terms of our loan agreement place restrictions on our operating and financial flexibility; new debt could further restrict flexibility.
• We have recently reduced the size of our organization and may encounter difficulties managing this development and strategic prioritization, which could disrupt operations and prevent anticipated benefits and savings.
• We are early in our development efforts; inability to advance product candidates through clinical development, obtain regulatory approval, and commercialize them, or significant delays, would materially harm our business.
• Although many personnel have extensive experience, we have limited direct experience as a company in conducting clinical trials and managing a manufacturing facility.
• Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, potency, and purity of any of our product candidates, preventing or delaying development, regulatory approval, and commercialization.
• Our business could be adversely affected by the effects of health epidemics in regions where we, our partners, or other third parties rely on significant facilities or operations.
• We may rely on third parties to manufacture our clinical product supplies and to produce and process our product candidates, if licensed.
• We cannot guarantee that our product candidates will show any functionality in the solid tumor microenvironment.
• Allogeneic hematopoietic cell transplantation (HCT) is a high-risk procedure that may result in complications or adverse events for patients unrelated to our product candidates.
• Our product candidates may cause undesirable side effects or have other properties that could halt clinical development, prevent regulatory approval, require trial expansion, limit commercial potential, or result in other significant negative consequences.
• If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
• The market opportunities for our product candidates may be relatively small, and our estimates of target patient populations may be inaccurate.
• We face significant competition, and our operating results will suffer if we fail to compete effectively.
• Manufacturing and administering our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development or scaling up.
• We may have difficulty validating our manufacturing process as we manufacture TCR-T therapy product candidates from an increasingly diverse patient population.
• The regulatory approval process is lengthy and time-consuming, and we may experience significant delays.
• We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements; denial or delay would impact revenue potential.
• Obtaining and maintaining regulatory approval in one jurisdiction does not guarantee success in others.
• If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope is not sufficiently broad, competitors could develop and commercialize similar products.
• We are currently, and expect in the future to be, party to material license or collaboration agreements, which may impose numerous obligations and restrictions on us.
• Third-party claims of intellectual property infringement, misappropriation, or other violations may prevent or delay our product candidate discovery and development efforts.
• We rely on third parties to help us conduct our clinical trials; failure to properly carry out duties or meet deadlines could prevent regulatory approval or commercialization.
• We have in the past and may in the future form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits.
• Rising inflation rates may result in increased operating costs and reduced liquidity and affect our ability to access credit.
• Our internal computer systems, or those used by our third-party CROs, clinical sites, or other contractors or consultants, may fail or suffer cybersecurity incidents, data breaches, or other unauthorized access, disrupting development programs.
• Cybersecurity incidents, loss of data or modification of information, and other disruptions could compromise information, prevent access to critical information, result in significant disruption, and expose us to liability.
• We may be subject to claims challenging the inventorship or ownership of our patent rights and other intellectual property.
• Patent terms may be inadequate to protect our competitive position; failure to obtain patent term extension and data exclusivity would materially harm our business.
• If our trademarks are not adequately protected, we may not be able to build name recognition.
• Certain of our in-licensed patent rights are, and our future owned and in-licensed patent rights may be, subject to a reservation of rights by one or more third parties, including government march-in rights, which may limit our ability to exclude competitors.
• If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization.
• Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
• We could be subject to securities class action litigation.
• Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.

Future Outlook

The company anticipates initiating a registrational trial for its lead product candidate, TSC-101, in the second quarter of 2026, pending further regulatory feedback. It also plans to initiate a Phase 1 study for its expanded heme program candidates, TSC-102-A01 and TSC-102-A03, in the second half of 2026. Preclinical efforts for solid tumors will now focus on an in vivo engineering platform, which is believed to be a more cost-efficient approach for off-the-shelf, multiplexed TCR-T therapy. The company expects to continue incurring significant losses for the foreseeable future, with expenses increasing as research and development programs advance, and will require substantial additional funding to complete development and commercialization. Annual cost savings of $45.0 million are expected in 2026 and 2027 from the recent strategic prioritization and workforce reduction. Future market expansion opportunities for TSC products include treating AML/MDS patients not in complete remission or those requiring minimal intensity conditioning, and potentially using TSC-101 as a chemotherapy and radiation-free conditioning regimen for non-malignant diseases, though these would require separate clinical trials.

Management Comments

• "We believe an in vivo approach represents a promising and more cost-efficient way to deliver off-the-shelf, multiplexed TCR-T therapy for solid tumors."
• "Our mission is to create life-changing T cell therapies for patients with cancer and autoimmune disorders."
• "We believe that in-house manufacturing capabilities substantially facilitate the successful early development of cell therapies."
• "We believe this enhancement [introducing the gene for CD8/ along with the TCR gene] has the potential to improve responses to TCR-T therapy in the clinic compared to engineering cytotoxic T cells alone."
• "We believe our diverse collection of therapeutic TCRs and our in-house cell therapy expertise constitute a meaningful competitive advantage."
• "We believe that these facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available to accommodate any such expansion of our operations."
• "We consider our relations with our employees to be good."
• "Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level."

Industry Context

StockSavvy.ai notes that TScan Therapeutics operates in the highly competitive and rapidly evolving biotechnology and cell therapy industry, characterized by intense focus on novel cancer treatments and autoimmune disorders. The strategic shift to prioritize hematologic malignancies and in vivo solid tumor engineering aligns with broader industry trends seeking more efficient and scalable cell therapy delivery methods. The company faces competition from established players like Gilead (Kite Pharma), Bristol-Myers Squibb (Juno Therapeutics), and AstraZeneca, as well as specialized TCR-T companies like Immatics and Adaptimmune, highlighting the need for differentiated efficacy and safety profiles. The increasing use of allogeneic HCT for heme malignancies provides a growing market, but also underscores the need for therapies that mitigate relapse and GvHD risks.

Comparison to Industry Standards

• The 100% durable response rate at 2 years post-HCT for 3 evaluable patients in the TSC-101 treatment arm (vs. 25% in control) is a strong early indicator, potentially outperforming historical relapse rates in AML/MDS post-HCT, which can be high.
• The reduction in manufacturing time from 17 to 12 days for TSC-101's commercial-ready process is a significant improvement in efficiency, addressing a common challenge in cell therapy manufacturing, where companies like Kite Pharma (Yescarta) and Novartis (Kymriah) have faced complexities and logistical hurdles in scaling production.
• The shift to in vivo engineering for solid tumors, partnering with a lentiviral-based platform specialist, reflects an industry-wide recognition of the challenges in ex vivo cell therapy for solid tumors, where CAR-T therapies have shown limited penetration and efficacy compared to heme malignancies.
• The Amgen collaboration for Crohn's disease targets positions TScan in the growing autoimmune space, similar to other biotech firms leveraging T-cell platforms beyond oncology, such as those exploring regulatory T-cell (Treg) therapies.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• A royalty agreement with one of the company's founders (amended June 2018, assigned to an affiliated entity in January 2021) requires a 1% royalty on net sales of any product covered by certain patents or applications held or controlled by the company as of the founder's last service date.

Stakeholder Impact

• Shareholders: Face potential dilution from future equity raises, stock price volatility, and limited influence on corporate matters due to concentrated ownership. The strategic shift and cost savings aim to improve long-term value, but current losses are a concern.
• Employees: A 30% workforce reduction (66 roles) impacts job security and morale, and may lead to a loss of institutional knowledge. The company aims to attract and retain talent through competitive compensation and benefits.
• Patients: Potential for new life-changing T-cell therapies for cancer (AML/MDS) and future autoimmune disorders. Early positive clinical data for TSC-101 offers hope, but risks of undesirable side effects or lack of efficacy in clinical trials remain.
• Partners/Collaborators: The Amgen collaboration continues to be a source of potential revenue. The strategic prioritization may influence future collaboration opportunities and focus.
• Creditors: The SVB Loan Agreement, secured by substantially all company assets (excluding intellectual property), includes covenants that restrict operational and financial flexibility.

Next Steps

• Initiate a registrational trial for TSC-101 in Q2 2026, pending further regulatory feedback.
• Initiate a Phase 1 study for TSC-102-A01 and TSC-102-A03 in H2 2026.
• Continue preclinical development of an in vivo engineering platform to deliver off-the-shelf TCR-T therapy for solid tumors.
• Continue identifying targets and developing potential treatment options for T cell-driven autoimmune disorders.
• Optimize existing manufacturing process for commercial viability, focusing on cost, consistency, and manufacturing success rate.
• Seek additional funding through equity offerings, debt financings, collaborations, strategic alliances, and/or licensing arrangements.
• Potentially expand the addressable market for TSC products to AML/MDS patients who do not achieve complete remission or those who could benefit from minimal intensity conditioning (requires separate clinical trials).
• Potentially explore the use of TSC-101 as a chemotherapy and radiation-free conditioning regimen for non-malignant diseases such as sickle cell anemia (requires separate clinical trials).

Key Dates

Recommendation

TScan Therapeutics presents a mixed bag. The positive clinical data for TSC-101 and the clear registrational path for the heme program are strong indicators of potential future success. However, the increased net losses, higher cash burn, and the strategic pause in the solid tumor program, coupled with a significant workforce reduction, highlight ongoing operational and financial challenges. The company's reliance on substantial future funding and the early stage of its autoimmune and in vivo solid tumor programs introduce considerable risk. While there's long-term potential, the immediate financial performance and strategic adjustments suggest a "hold" position until more definitive progress is made across its pipeline and financial stability improves.

Keywords

T-cell therapy, TCR-T, oncology, hematologic malignancies, AML, MDS, solid tumors, gene therapy, biotechnology, clinical trials, FDA approval, HA-2, CD45, autoimmune disorders, Amgen collaboration, manufacturing, preclinical development, in vivo engineering, immunotherapy